Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Bonds01:25

Drug-Receptor Bonds

5.2K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
5.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demographics, methods of use, and perceived benefits among patients with cancer who use cannabis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Toxicity assessment of airborne ultrafine particles: Role of transport emissions.

The Science of the total environment·2025
Same author

Toxicity of airborne nanoparticles: Facts and challenges.

Environment international·2024
Same author

Mithramycin and its analogs: Molecular features and antitumor action.

Pharmacology & therapeutics·2024
Same author

Efficient removal of toxicity associated to wastewater treatment plant effluents by enhanced Soil Aquifer Treatment.

Journal of hazardous materials·2024
Same author

Linking the use of reclaimed water to indicators of crop stress by metabolomic and transcriptomic analyses. A tool to compare water irrigation quality.

The Science of the total environment·2023

Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response
05:01

Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response

Published on: June 14, 2024

2.4K

Noncovalent Binding to DNA: Still a Target in Developing Anticancer Agents.

José Portugal1, Francisca Barceló

  • 1Instituto de Biologia Molecular de Barcelona, CSIC, Parc Cientific de Barcelona Baldiri Reixac, 10, Barcelona E-08028, Spain.

Current Medicinal Chemistry
|September 6, 2016
PubMed
Summary

This review explores DNA-binding compounds, crucial for antitumor drugs. Understanding how these molecules interact with DNA is key to developing effective cancer therapies and manipulating gene expression.

More Related Videos

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
06:43

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

19.2K
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.4K

Related Experiment Videos

Last Updated: Mar 15, 2026

Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response
05:01

Author Spotlight: Developing Novel Anticancer Therapeutics Targeting the DNA Damage Response

Published on: June 14, 2024

2.4K
A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
06:43

A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents

Published on: August 31, 2013

19.2K
Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.4K

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Genetics

Background:

  • DNA-binding compounds are vital in medicine, particularly as antitumor drugs.
  • The precise mechanisms of action for many DNA-binding agents are not fully understood.
  • Noncovalent DNA binders, including intercalators and groove binders, represent significant therapeutic agents.

Purpose of the Study:

  • To critically review two main classes of noncovalent DNA-binding molecules: intercalators and groove binders.
  • To discuss the mechanisms by which these compounds interact with DNA, including G-quadruplexes and topoisomerase inhibition.
  • To examine the impact of DNA-binding compounds on gene transcription and protein binding in cancer cells.

Main Methods:

  • Literature review of DNA-binding compounds, focusing on intercalators and groove binders.
  • Analysis of molecular interactions with DNA structures like G-quadruplexes.
  • Discussion of in vitro and cellular studies on transcription modulation and protein competition.

Main Results:

  • Intercalators insert between DNA base pairs; groove binders fit into DNA grooves.
  • DNA-binding compounds can target specific DNA structures (e.g., G-quadruplexes) and inhibit topoisomerases.
  • These compounds affect gene transcription and compete with protein factors for promoter binding sites.

Conclusions:

  • Both natural and synthetic DNA-binding compounds offer potential for cancer therapy by manipulating gene expression.
  • Further research into molecular design can yield agents with specific DNA-targeting capabilities.
  • Genome-wide studies are essential for understanding the impact of these compounds on cancer progression and treatment outcomes.